search
Back to results

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (DC-HIV04)

Primary Purpose

HIV Infections

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
a1DC + inactivated whole autologous HIV
a1DC + conserved HIV peptides
a1DC + no antigen
pgDC + inactivated whole autologous HIV
pgDC + conserved HIV peptides
pgDC + no antigen
Sponsored by
Sharon Riddler
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring dendritic cell, vaccine, immunogenicity, HIV, vaccination, immune system

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. HIV-1 infection, documented by any FDA-approved assay. NOTE: The term 'licensed' refers to a US FDA approved kit, which is required for all investigational new drug (IND) studies.
  2. Receiving continuous ART for at least 24 months (defined as no interruptions longer than 14 consecutive days) and with no changes in the components of the ART for at least 8 weeks prior to study entry. A change in formulation (for example tenofovir disaproxil fumarate to tenofovir alafenamide) will not be considered a change in ART.
  3. Screening CD4+ cell count ≥350cells/mm3 obtained within 60 days prior to study entry by any US laboratory that has a CLIA certification or its equivalent.
  4. Plasma HIV-1 RNA levels < 50 copies/ml for at least 24 months prior to study entry using a FDA-approved assay performed by any laboratory that has a CLIA certification or its equivalent. Participants must have at least one documented HIV-1 RNA less than 50 copies/ml >24 months prior to study entry and at least one HIV-1 RNA less than 50 copies/ml within 12 months prior to study entry. All available HIV-1 RNA measurements must be < 50 copies/ml during the 24 months prior to study entry except as allowed by the following note.

    NOTE: Unconfirmed plasma HIV-1 RNA > 50 copies/ml but <200 copies/mL is allowed if followed by a subsequent value < 50 copies/ml.

  5. Screening HIV-1 RNA levels <50 copies/mL using a FDA-approved assay performed by any laboratory that has a CLIA certification or its equivalent within 60 days prior to entry.
  6. Men and women age 18 to 65 years, inclusive.
  7. The following laboratory values obtained within 60 days prior to entry:

    Hemoglobin ≥10 g/dL Absolute neutrophil count (ANC) ≥1000/mm3 Platelet count ≥100,000/mm3 Creatinine ≤ 1.5x upper limit of normal (ULN) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (SGPT) ≤2.5x ULN

  8. Ability and willingness of participant to provide informed consent.
  9. In the opinion of the investigator, no medical, mental health or other condition that precludes participation.
  10. For females of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to entry by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point-of-care (POC)/ CLIA-waived test. Females of reproductive potential include women who have not been post-menopausal for at least 12 consecutive months, (i.e., who have had menses within the preceding 12 months) or women who have not undergone surgical sterilization (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation or salpingectomy). Self- report is acceptable documentation of menopause and sterilization.
  11. All participants must agree not to participate in the conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the participant/partner must use at least one reliable form of contraception (condoms, with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an IUD; or hormone-based contraceptive), while receiving study treatment and for 12 weeks following the final study vaccine.

Exclusion Criteria:

  1. Currently breastfeeding or pregnant
  2. Known allergy/sensitivity or any hypersensitivity to components of study vaccine or their formulation.
  3. Known chronic inflammatory conditions such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis), chronic pancreatitis, or autoimmune hepatitis, myositis, or myopathy.
  4. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  5. Serious medical illness that requires systemic treatment and/or hospitalization within 30 days prior to entry.
  6. Use of systemic immunomodulators (eg, interleukins, interferons, cyclosporine), systemic cytotoxic chemotherapy, or investigational therapy within 60 days prior to study entry.

    NOTE: Participants receiving stable physiologic doses of glucocorticoids, defined as the equivalent of prednisone ≤10 mg/day, will not be excluded. Stable physiologic glucocorticoid doses should not be discontinued for the duration of the study. In addition, participants receiving inhaled or topical corticosteroids, or topical imiquimod will not be excluded.

  7. Participation on any HIV immunotherapy or therapeutic vaccination trials within 6 months prior to study entry.
  8. History of positive HCV antibody with detectable HCV RNA in plasma within 48 weeks prior to study entry.

    NOTE: Persons with positive HCV Ab but negative plasma HCV RNA are allowed to participate. Sites must document negative HCV RNA within 24 weeks of study entry.

  9. History of positive HBsAg within 48 weeks prior to study entry.
  10. Treatment for hepatitis C within 6 months prior to study entry.
  11. Initiation of ART during acute HIV-1 infection (as determined by the site investigator by history and/or available medical records).
  12. Lack of adequate venous access that, in the opinion of the investigator, would interfere with study requirements.

Sites / Locations

  • AIDS Clinical Trials Unit/The Ohio State UniversityRecruiting
  • HIV/AIDS Clinical Research Unit / University of PittsburghRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Active Comparator

Experimental

Experimental

Active Comparator

Arm Label

ARM A

ARM B

ARM C

ARM D

ARM E

ARM F

Arm Description

a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose

a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose

a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose

pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose

pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose

pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose

Outcomes

Primary Outcome Measures

Safety and tolerability of six immunizations (10e7 DCs per dose) of DC-whole virus and DC-peptide vaccines in HIV-1 infected participants on effective ART
Occurrence of Grade ≥ 3 AE including signs/symptoms, lab toxicities, and/or clinical events that are possibly, probably, or definitely related to study treatment (as judged by the site investigator, blinded to treatment arm) at any time from the initial dose of DC vaccine product to end of study follow-up.
Efficacy of six immunizations (10e7 DCs per dose) of DC-whole virus and DC-peptide vaccines in HIV-1 infected participants on effective ART
Change in HIV-specific CD8 and T-cell immune response as measured by ELISPOT between the vaccine arms.

Secondary Outcome Measures

Relative efficacy of the DC-HIV vaccines in priming HIV-specific-CD8+ T cells
Change in the ability of the DC-HIV vaccines to inhibit autologous HIV in an ex vivo virus inhibition assay.
Effect of DC-HIV vaccination on the level of persistent viremia in plasma
Change in plasma HIV-1 RNA viral load as measured by single copy assay (SCA)
Effect of DC-HIV vaccination on HIV specific CD8 T-cell polyfunctional responses
Change in HIV specific CD8 T-cell polyfunctional responses as measured by intracellular cytokine staining using flow cytometry.
Assess the impact of DC-HIV vaccination on levels of cell-associated HIV-1 RNA and DNA
Changes in cell-associated HIV-1 RNA and DNA levels and assessment of the differences between the vaccine arms
Effect of DC-HIV vaccination on the levels of immune activation
Changes in markers of cellular immune cell activation and assessment of the differences between the vaccine arms
Effect of DC-HIV vaccination on the levels of systemic inflammation
Changes in soluble markers of systemic inflammation and assessment of the differences between the vaccine arms

Full Information

First Posted
November 20, 2018
Last Updated
October 4, 2023
Sponsor
Sharon Riddler
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT03758625
Brief Title
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure
Acronym
DC-HIV04
Official Title
A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 30, 2018 (Actual)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Sharon Riddler
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will be done in people living with HIV to see if an investigational vaccine made from a person's own white blood cells is safe and tolerated. This study will also look at the body's immune response to the vaccine and evaluate four different methods of making the vaccine to see which method may result in better immune responses.
Detailed Description
Despite the availability of strong medicines for HIV infection, there is no cure for the infection. The current anti-HIV drugs, used in combination, are effective in slowing the growth of the virus and delaying the progression of the infection. There is increasing information to suggest that a vigorous immune response (a strong response of the body to fight infection) to HIV may also result in improved control of the HIV infection. Such strong immune responses are found in a small number of HIV-infected individuals, but not in the majority. Dendritic cells, or DCs, are a type of white blood cell that works together with other immune cells to fight infection. The DCs role is to bring substances foreign to the body, such as viruses including HIV or cancer cell proteins, to the body's immune system. Large numbers of DCs can be made from blood samples and administered back to the same person as an individualized vaccine. Vaccines made from DCs have been studied in HIV and numerous types of cancer. The vaccines will be created by two different laboratory methods, standard or improved, using an individual's own DCs and either an individual's own inactive HIV that has been killed with heat or manmade HIV proteins called peptides. The peptides have not been studied for this use in humans, and these vaccines are not approved by the Food and Drug Administration (FDA) to prevent or treat HIV infection. This study will be done in two steps. During Step 1 (Entry-Week 12), participants will have 4 study visits for tests, procedures and exams. At Week 4, participants will be randomized by chance into one of six study groups, like rolling dice. Four of the study groups will receive a DC-HIV vaccine while two of the study groups will receive a "control" vaccine with only DCs. Participants will have a 4:1 chance of receiving a DC-HIV study vaccine. Group 1: enhanced DC-HIV vaccine with inactive HIV Group 2: enhanced DC-HIV vaccine with HIV peptides Group 3: enhanced DCs only (control) Group 4: classic DC-HIV vaccine with inactive HIV Group 5: classic DC-HIV vaccine with HIV peptides Group 6: classic DCs only (control) Each participant will receive 6 study vaccinations at 4-week intervals beginning at Week 12. Researchers will compare the results from participants who get the active study vaccines with results from participants who get the control vaccines. Participants, the researchers and the clinic staff will not know which vaccine participants are getting. In Step 2 (Weeks 12 - 80), participants will have 18 study visits to receive the 6 study vaccinations and for tests to monitor health and safety and to see how the study vaccine affects the immune system and the virus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
dendritic cell, vaccine, immunogenicity, HIV, vaccination, immune system

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double-blind, multi-arm
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ARM A
Arm Type
Experimental
Arm Description
a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
Arm Title
ARM B
Arm Type
Experimental
Arm Description
a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
Arm Title
ARM C
Arm Type
Active Comparator
Arm Description
a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
Arm Title
ARM D
Arm Type
Experimental
Arm Description
pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
Arm Title
ARM E
Arm Type
Experimental
Arm Description
pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
Arm Title
ARM F
Arm Type
Active Comparator
Arm Description
pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
Intervention Type
Biological
Intervention Name(s)
a1DC + inactivated whole autologous HIV
Intervention Description
Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
Intervention Type
Biological
Intervention Name(s)
a1DC + conserved HIV peptides
Intervention Description
Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
Intervention Type
Biological
Intervention Name(s)
a1DC + no antigen
Intervention Description
Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
Intervention Type
Biological
Intervention Name(s)
pgDC + inactivated whole autologous HIV
Intervention Description
Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
Intervention Type
Biological
Intervention Name(s)
pgDC + conserved HIV peptides
Intervention Description
Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
Intervention Type
Biological
Intervention Name(s)
pgDC + no antigen
Intervention Description
Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
Primary Outcome Measure Information:
Title
Safety and tolerability of six immunizations (10e7 DCs per dose) of DC-whole virus and DC-peptide vaccines in HIV-1 infected participants on effective ART
Description
Occurrence of Grade ≥ 3 AE including signs/symptoms, lab toxicities, and/or clinical events that are possibly, probably, or definitely related to study treatment (as judged by the site investigator, blinded to treatment arm) at any time from the initial dose of DC vaccine product to end of study follow-up.
Time Frame
Step 2-Week 0 (overall Study Week 12) to overall Study Week 80
Title
Efficacy of six immunizations (10e7 DCs per dose) of DC-whole virus and DC-peptide vaccines in HIV-1 infected participants on effective ART
Description
Change in HIV-specific CD8 and T-cell immune response as measured by ELISPOT between the vaccine arms.
Time Frame
Baseline to Step 2-Week 22 (overall Study Week 34)
Secondary Outcome Measure Information:
Title
Relative efficacy of the DC-HIV vaccines in priming HIV-specific-CD8+ T cells
Description
Change in the ability of the DC-HIV vaccines to inhibit autologous HIV in an ex vivo virus inhibition assay.
Time Frame
Baseline to Step 2-Week 22 (overall Study Week 34)
Title
Effect of DC-HIV vaccination on the level of persistent viremia in plasma
Description
Change in plasma HIV-1 RNA viral load as measured by single copy assay (SCA)
Time Frame
Baseline to Step 2-Week 22 (overall Study Week 34)
Title
Effect of DC-HIV vaccination on HIV specific CD8 T-cell polyfunctional responses
Description
Change in HIV specific CD8 T-cell polyfunctional responses as measured by intracellular cytokine staining using flow cytometry.
Time Frame
Baseline to Step 2-Week 22 (overall Study Week 34)
Title
Assess the impact of DC-HIV vaccination on levels of cell-associated HIV-1 RNA and DNA
Description
Changes in cell-associated HIV-1 RNA and DNA levels and assessment of the differences between the vaccine arms
Time Frame
Baseline to Step 2-Week 22 (overall Study Week 34)
Title
Effect of DC-HIV vaccination on the levels of immune activation
Description
Changes in markers of cellular immune cell activation and assessment of the differences between the vaccine arms
Time Frame
Baseline to Step 2-Week 22 (overall Study Week 34)
Title
Effect of DC-HIV vaccination on the levels of systemic inflammation
Description
Changes in soluble markers of systemic inflammation and assessment of the differences between the vaccine arms
Time Frame
Baseline to Step 2-Week 22 (overall Study Week 34)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HIV-1 infection, documented by any FDA-approved assay. NOTE: The term 'licensed' refers to a US FDA approved kit, which is required for all investigational new drug (IND) studies. Receiving continuous ART for at least 24 months (defined as no interruptions longer than 14 consecutive days) and with no changes in the components of the ART for at least 8 weeks prior to study entry. A change in formulation (for example tenofovir disaproxil fumarate to tenofovir alafenamide) will not be considered a change in ART. Screening CD4+ cell count ≥350cells/mm3 obtained within 60 days prior to study entry by any US laboratory that has a CLIA certification or its equivalent. Plasma HIV-1 RNA levels < 50 copies/ml for at least 24 months prior to study entry using a FDA-approved assay performed by any laboratory that has a CLIA certification or its equivalent. Participants must have at least one documented HIV-1 RNA less than 50 copies/ml >24 months prior to study entry and at least one HIV-1 RNA less than 50 copies/ml within 12 months prior to study entry. All available HIV-1 RNA measurements must be < 50 copies/ml during the 24 months prior to study entry except as allowed by the following note. NOTE: Unconfirmed plasma HIV-1 RNA > 50 copies/ml but <200 copies/mL is allowed if followed by a subsequent value < 50 copies/ml. Screening HIV-1 RNA levels <50 copies/mL using a FDA-approved assay performed by any laboratory that has a CLIA certification or its equivalent within 60 days prior to entry. Men and women age 18 to 70 years, inclusive. The following laboratory values obtained within 60 days prior to entry: Hemoglobin ≥10 g/dL Absolute neutrophil count (ANC) ≥1000/mm3 Platelet count ≥100,000/mm3 Creatinine ≤ 1.5x upper limit of normal (ULN) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (SGPT) ≤2.5x ULN Ability and willingness of participant to provide informed consent. In the opinion of the investigator, no medical, mental health or other condition that precludes participation. For females of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to entry by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point-of-care (POC)/ CLIA-waived test. Females of reproductive potential include women who have not been post-menopausal for at least 12 consecutive months, (i.e., who have had menses within the preceding 12 months) or women who have not undergone surgical sterilization (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation or salpingectomy). Self- report is acceptable documentation of menopause and sterilization. All participants must agree not to participate in the conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the participant/partner must use at least one reliable form of contraception (condoms, with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an IUD; or hormone-based contraceptive), while receiving study treatment and for 12 weeks following the final study vaccine. Exclusion Criteria: Currently breastfeeding or pregnant Known allergy/sensitivity or any hypersensitivity to components of study vaccine or their formulation. Known chronic inflammatory conditions such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis), chronic pancreatitis, or autoimmune hepatitis, myositis, or myopathy. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. Serious medical illness that requires systemic treatment and/or hospitalization within 30 days prior to entry. Use of systemic immunomodulators (eg, interleukins, interferons, cyclosporine), systemic cytotoxic chemotherapy, or investigational therapy within 60 days prior to study entry. NOTE: Participants receiving stable physiologic doses of glucocorticoids, defined as the equivalent of prednisone ≤10 mg/day, will not be excluded. Stable physiologic glucocorticoid doses should not be discontinued for the duration of the study. In addition, participants receiving inhaled or topical corticosteroids, or topical imiquimod will not be excluded. Participation on any HIV immunotherapy or therapeutic vaccination trials within 6 months prior to study entry. History of positive HCV antibody with detectable HCV RNA in plasma within 48 weeks prior to study entry. NOTE: Persons with positive HCV Ab but negative plasma HCV RNA are allowed to participate. Sites must document negative HCV RNA within 24 weeks of study entry. History of positive HBsAg within 48 weeks prior to study entry. Treatment for hepatitis C within 6 months prior to study entry. Initiation of ART during acute HIV-1 infection (as determined by the site investigator by history and/or available medical records). Lack of adequate venous access that, in the opinion of the investigator, would interfere with study requirements.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jamie Fullerton, MPPM
Phone
412-383-1675
Email
idelucaj@upmc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Sherri Karas, MEd
Phone
412-383-1313
Email
schesx@upmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sharon Riddler, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Bernard Macatangay, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
John Mellors, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Study Chair
Facility Information:
Facility Name
AIDS Clinical Trials Unit/The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lindsay Summers, MPH
Phone
614-293-8529
Email
Lindsay.Summers@osumc.edu
First Name & Middle Initial & Last Name & Degree
Keiichi Koshino, BSN, RN
Phone
614-293-4855
Email
Keiichi.Koshino@osumc.edu
First Name & Middle Initial & Last Name & Degree
Susan Koletar, MD
First Name & Middle Initial & Last Name & Degree
Carlos Malvestutto, MD
Facility Name
HIV/AIDS Clinical Research Unit / University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jamie Fullerton
Phone
412-383-1675
Email
idelucaj@upmc.edu
First Name & Middle Initial & Last Name & Degree
Sherri Karas
Phone
412-383-1313
Email
schesx@upmc.edu
First Name & Middle Initial & Last Name & Degree
Sharon Riddler, MD, MPH
First Name & Middle Initial & Last Name & Degree
Bernard Macatangay, MD
First Name & Middle Initial & Last Name & Degree
Kaleab Abebe, PhD
First Name & Middle Initial & Last Name & Degree
Ken Ho, MD
First Name & Middle Initial & Last Name & Degree
Deborah McMahon, MD
First Name & Middle Initial & Last Name & Degree
Madhu Choudhary, MD
First Name & Middle Initial & Last Name & Degree
Joshua Cyktor, PhD
First Name & Middle Initial & Last Name & Degree
John Mellors, MD
First Name & Middle Initial & Last Name & Degree
Yen-Michael Hsu, MD, PhD, FCAP

12. IPD Sharing Statement

Learn more about this trial

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

We'll reach out to this number within 24 hrs